Hong Kong’s Department of Health (DH) announced plans to establish a new medical products regulatory agency called the Hong Kong Centre for Medical Products Regulation (CMPR) by the end of 2026.
Taiwan’s Hanchorbio Inc. is out-licensing its breakthrough checkpoint inhibitor, HCB-101, to Shanghai Henlius Biotech Inc. in a deal worth more than $200 million.
Torrent Pharmaceutical Ltd. will buy J. B. Chemicals and Pharmaceuticals Ltd. (JB Pharma) from private equity firm KKR & Co. Inc. at an equity valuation of ₹256.89 billion (US$3 billion), which will then merge into one entity under Torrent Pharma.
Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting up-front, near-term payments and R&D funding, could end up with about $1.5 billion in milestones and options payments plus tiered royalties on net sales.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Achieve Life Sciences, BMS, Innovent, Omeros, Schrödinger.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aicella, Biocryst, Calico, Channel, Invetech, Mabwell, Neopharmed, Turnstone, Xoma.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alebund, Altimmune, Alto, Crispr, Edgewise, Gri, I-Mab, Invivyd, Lisata, Metabolics, Opus, Pfizer, Viatris.
RSS
